Abstract:BACKGROUND Programmed death ligand 1 (PD-L1) immunotherapy remains poorly efficacious in colorectal cancer (CRC). The recepteur d’origine nantais (RON) receptor tyrosine kinase plays an important role in regulating tumor immunity. AIM To identify the patterns of RON and PD-L1 expression and explore their clinical significance in CRC. METHODS Gene expression data from the Gene Expression Omnibus database (GEO; n = 290) and patients at the First Affiliated Hospital, Zhejiang University School of Medicine (FAHZUSM; n = 381) were analyzed to determine the prognostic value of RON and PD-L1 expression within the tumor microenvironment of CRC. HT29 cell line was treated with BMS-777607 to explore the relationship between RON activity and PD-L1 expression. Signaling pathways and protein expression perturbed by RON inhibition were evaluated by cellular immunofluorescence and Western blot. RESULTS In the GEO patient cohort, cut-off values for RON and PD-L1 expression were determined to be 7.70 and 4.3, respectively. Stratification of patients based on these cutoffs demonstrated that high expression of RON and PD-L1 was associated with a poor prognosis. In the FAHZUSM cohort, rates of high expression of RON in tumor cells, high PD-L1 expression in tumor cells and tumor infiltrating monocytes, and both high RON and high PD-L1 expression in the tumor microenvironment were 121 (32%), 43 (11%), 91 (24%), and 51 (13.4%), respectively. High expression of RON was significantly correlated with high expression of PD-L1 in the tumor cell compartment (P < 0.001). High expression of RON and that of PD-L1 were independent prognostic factors for poorer overall survival. Concurrent high expression of both RON and PD-L1 in the tumor microenvironment was significantly associated with a poor prognosis. In vitro, BMS-777607 inhibited the phosphorylation of RON, inhibited PD-L1 expression, and attenuated activation of the ERK1/2 and AKT signaling pathways in CRC cells. CONCLUSION RON, PD-L1, and their crosstalk are significant in predicting the prognostic value of CRC. Moreover, phosphorylation of RON upregulates PD-L1 expression, which provides a novel approach to immunotherapy in CRC.

Upregulation of Rab31 is associated with poor prognosis and promotes colorectal carcinoma proliferation via the mTOR/p70S6K/Cyclin D1 signalling pathway

Ribonucleotide Reductase Large Subunit M1 Predicts Poor Survival Due To Modulation Of Proliferative And Invasive Ability Of Gastric Cancer

RAB31 drives extracellular vesicle fusion and cancer-associated fibroblast formation leading to oxaliplatin resistance in colorectal cancer

Decreased Expression of Rab27A and Rab27B Correlates with Metastasis and Poor Prognosis in Colorectal Cancer.

Upregulation of CPE promotes cell proliferation and tumorigenicity in colorectal cancer

Increased RAB31 Expression in Cancer-Associated Fibroblasts Promotes Colon Cancer Progression Through HGF-MET Signaling.

Pathological Significance of Abnormal Recepteur D’origine Nantais and Programmed Death Ligand 1 Expression in Colorectal Cancer

Overexpression of G protein-coupled receptor 31 as a poor prognosticator in human colorectal cancer

RAB10 promotes breast cancer proliferation migration and invasion predicting a poor prognosis for breast cancer

Analysis of Correlation between Rab1A Expression and its Prognosis in Cancers: a Meta-Analysis

Overexpression of Protein Regulator of Cytokinesis 1 Facilitates Tumor Growth and Indicates Unfavorable Prognosis of Patients with Colon Cancer

Ribosomal Protein S15a Promotes Malignant Transformation And Predicts Poor Outcome In Colorectal Cancer Through Misregulation Of P53 Signaling Pathway

Mir-204-5p Inhibits Proliferation and Invasion and Enhances Chemotherapeutic Sensitivity of Colorectal Cancer Cells by Downregulating RAB22A.

miR-31 Promotes the Proliferation of Colorectal Cancer Cells Through Activating NF-κB Signal Pathway

MicroRNA-31 Activates the RAS Pathway and Functions as an Oncogenic MicroRNA in Human Colorectal Cancer by Repressing RAS p21 GTPase Activating Protein 1 (RASA1)

The association of aberrant expression of NLRP3 and p-S6K1 in colorectal cancer

Biology of Human Tumors miR-2045 p Inhibits Proliferation and Invasion and Enhances Chemotherapeutic Sensitivity of Colorectal Cancer Cells by Downregulating RAB 22 A

Overexpression of RAB31 in gastric cancer is associated with released exosomes and increased tumor cell invasion and metastasis

Role of MUC20 overexpression as a predictor of recurrence and poor outcome in colorectal cancer

Elevated Microrna-31 Expression Regulates Colorectal Cancer Progression By Repressing Its Target Gene Satb2

Clinical value and potential association of Rab1A and FoxM1 aberrant expression in colorectal cancer